Earnings results for Forma Therapeutics (NASDAQ:FMTX)
Forma Therapeutics Holdings, Inc. is expected* to report earnings on 08/13/2021 before market open. The report will be for the fiscal Quarter ending Jun 2021. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.79. The reported EPS for the same quarter last year was $-4.58.
Forma Therapeutics last announced its earnings results on May 13th, 2021. The reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). Forma Therapeutics has generated ($3.22) earnings per share over the last year (($6.69) diluted earnings per share). Earnings for Forma Therapeutics are expected to decrease in the coming year, from ($3.10) to ($3.73) per share. Forma Therapeutics has confirmed that its next quarterly earnings report will be published on Friday, August 13th, 2021. Forma Therapeutics will be holding an earnings conference call on Friday, August 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Forma Therapeutics (NASDAQ:FMTX)
6 Wall Street analysts have issued ratings and price targets for Forma Therapeutics in the last 12 months. Their average twelve-month price target is $60.50, predicting that the stock has a possible upside of 160.44%. The high price target for FMTX is $68.00 and the low price target for FMTX is $54.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Forma Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $60.50, Forma Therapeutics has a forecasted upside of 160.4% from its current price of $23.23. Forma Therapeutics has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Forma Therapeutics (NASDAQ:FMTX)
Forma Therapeutics does not currently pay a dividend. Forma Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Forma Therapeutics (NASDAQ:FMTX)
In the past three months, Forma Therapeutics insiders have not sold or bought any company stock. Only 4.32% of the stock of Forma Therapeutics is held by insiders. 84.66% of the stock of Forma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Forma Therapeutics (NASDAQ:FMTX
Earnings for Forma Therapeutics are expected to decrease in the coming year, from ($3.10) to ($3.73) per share. The P/E ratio of Forma Therapeutics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Forma Therapeutics is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Forma Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here